Diabetes Obesity & Metabolism

Papers
(The H4-Index of Diabetes Obesity & Metabolism is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Diabetes, Obesity and Metabolism365
342
Issue Information244
Front Cover232
Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study173
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020156
Development of the health economic model for type 2 diabetes considering glycaemic variability140
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry135
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pum117
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis114
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis112
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”110
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic104
Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice103
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin101
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes99
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes98
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Resul96
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status96
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study90
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia85
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada78
Higher post‐prandial glucose excursions in youth with type 1 diabetes and celiac disease: Time to change the bolus?76
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c73
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial69
Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in typ68
Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabet68
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity68
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes68
Pathway‐Specific Polygenic Risk Scores and Cardiorenal Complications in Asians With Type 2 Diabetes62
Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study62
CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination62
SemaGBA : A System Dynamics Model of the Semaglutide‐Responsive Gut‐Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight60
Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP ‐1 Receptor Agonists: A Machine Learni60
Maternal Pregestational and Gestational Diabetes and Neuropsychiatric Risk in Offspring: A Binational Cohort Study60
Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide59
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis58
Spillover effects of a nudge‐based dietary intervention on physical activity and sleep among adults with type 2 diabetes: Evidence from a randomised controlled trial57
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial54
Involvement of the FTO A > T polymorphism in body composition and lipid profile changes after aerobic training in adults with overweight and obesity53
Incidence of chronic kidney disease among adults with prediabetes in the CURE ‐ CKD registry, 201352
Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’52
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity51
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment51
Long‐term effects of metformin on offspring health: A review of current evidence and future directions51
Adaptive bolus calculators for people with type 1 diabetes: A systematic review51
Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses50
Effects of CB1R inverse agonist, INV ‐202, in patients with features of metabolic syndrome. A rand50
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’50
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis49
Cardiorenal Outcomes of Empagliflozin Versus Dapagliflozin in Secondary Prevention Among Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Nationwide Cohort Study49
The effects of antihypertensive drugs on glucose metabolism49
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes49
0.48234415054321